Similar to dopamine (DA), cannabinoids strongly influence prefrontal cortical functions, such as working memory, emotional learning, and sensory perception. Although endogenous cannabinoid receptors (CB 1 Rs) are abundantly expressed in the prefrontal cortex (PFC), very little is known about endocannabinoid (eCB) signaling in this brain region. Recent behavioral and electrophysiological evidence has suggested a functional interplay between the dopamine and cannabinoid receptor systems, although the cellular mechanisms underlying this interaction remain to be elucidated. We examined this issue by combining neuroanatomical and electrophysiological techniques in PFC of rats and mice (both genders). Using immunoelectron microscopy, we show that CB 1 Rs and dopamine type 2 receptors (D 2 Rs) colocalize at terminals of symmetrical, presumably GABAergic, synapses in the PFC. Indeed, activation of either receptor can suppress GABA release onto layer 5 pyramidal cells. Furthermore, coactivation of both receptors via repetitive afferent stimulation triggers eCB-mediated long-term depression of inhibitory transmission (I-LTD). This I-LTD is heterosynaptic in nature, requiring glutamate release to activate group I metabotropic glutamate receptors. D 2 Rs most likely facilitate eCB signaling at the presynaptic site as disrupting postsynaptic D 2 R signaling does not diminish I-LTD. Facilitation of eCB-LTD may be one mechanism by which DA modulates neuronal activity in the PFC and regulates PFC-mediated behavior in vivo.
Introduction
Dopaminergic innervation of the prefrontal cortex (PFC) strongly modulates high-level cognitive processes (Le Moal and Simon, 1991; Goldman-Rakic, 1998; Seamans and Yang, 2004) . Unlike fast ionotropic neurotransmitters, dopamine (DA) does not directly mediate synaptic transmission but affects it by altering the cellular or synaptic properties of target neurons (Greengard, 2001; Seamans and Yang, 2004; Iversen and Iversen, 2007) . The recent link between DA and endocannabinoids (eCBs) (van der Stelt and Di Marzo, 2003; Laviolette and Grace, 2006) is particularly interesting in the PFC given the well known hallucinogenic effects of exogenous cannabinoids and the potential eCB association with neuropsychiatric disorders that reflect PFC dysfunction (Ujike and Morita, 2004; Koethe et al., 2009; Sewell et al., 2009 ). However, it remains unclear exactly how eCBs regulate PFC function and whether DA plays a role in this regulation.
Short-and long-term synaptic plasticity mediated by eCBs has been reported in several brain regions (for recent reviews, see Chevaleyre et al., 2006; Lovinger, 2008; Heifets and Castillo, 2009; Kano et al., 2009) . Recent evidence in the midbrain suggests that DA, via D 2 -like receptors (D 2 Rs), can facilitate eCB signaling and eCB-mediated plasticity (Melis et al., 2004; Kreitzer and Malenka, 2005; Yin and Lovinger, 2006; Kreitzer and Malenka, 2007; Shen et al., 2008) . Consistent with the observation that D 2 R activation increases striatal levels of the eCB anandamide in vivo (Giuffrida et al., 1999) , it was suggested that DA acts via postsynaptic D 2 Rs by promoting the production of eCBs. However, like CB 1 Rs, D 2 Rs are coupled to G i/o -proteins and their activation leads to the inhibition of adenylyl cyclase (AC), resulting in a reduction of cAMP levels and protein kinase A (PKA) activity. The observation that D 2 Rs may be present at presynaptic locations in the PFC (Fadda et al., 1984; Seamans et al., 2001 ) raises the possibility that CB 1 Rs and D 2 Rs may colocalize on the same axon terminals and perhaps be coactivated by physiological synaptic activity. It is unknown how coincident activation of presynaptic CB 1 Rs and D 2 Rs in the PFC may affect transmitter release.
Most studies on eCB-mediated plasticity have concentrated on excitatory synapses, and the PFC is no exception. Pharmacological activation of CB 1 Rs suppresses excitatory inputs to layer 5 pyramidal cells in rodent PFC (Auclair et al., 2000; Lafourcade et al., 2007) , and repetitive stimulation in PFC can elicit long-term depression of excitatory transmission (E-LTD) (Lafourcade et al., 2007) . However, given that a balance of excitation and inhibition shapes neuronal excitability and network firing patterns, knowledge of how eCBs influence inhibitory transmission in the PFC will be necessary to predict the functional impact of eCB signaling in this structure. Here, we investigate eCB signaling at inhibitory synapses in the PFC and demonstrate facilitation of inhibitory LTD (I-LTD) by the dopaminergic system. Our findings suggest a potential synaptic link between eCB and DA function in the PFC. Dysregulation of this crosstalk may play a role in neuropsychiatric disorders, such as schizophrenia.
Materials and Methods
Double CB 1 R/D 2 R immunocytochemistry for electron microscopy. Female mice (n ϭ 3, 2 months old, C57BL/6 strain) were deeply anesthetized with chloral hydrate (400 mg/kg body weight). CB 1 R Ϫ/Ϫ knock-out mice (n ϭ 2; kindly provided by Dr. Giovanni Marsicano, Institute François Magendie, Bordeaux, France) (Marsicano et al., 2002) were used as controls of CB 1 R antibody specificity. All animals were transcardially perfused with phosphate-buffered solution (PB) (0.1 M, pH 7.4) and then fixed by 500 ml of 0.1% glutaraldehyde, 4% formaldehyde (freshly depolymerized from paraformaldehyde), and 0.2% picric acid in 0.1 M PB, pH 7.4, prepared at 4°C. Tissue blocks were extensively rinsed in 0.1 M PB, pH 7.4. Rostral vibrosections containing the PFC were cut at 50 m and collected in 0.1 M PB, pH 7.4, at room temperature (RT). Sections were preincubated in a blocking solution of 10% bovine serum albumin (BSA), 0.1% sodium azide, and 0.02% saponin prepared in Tris-HClbuffered saline (TBS), pH 7.4, for 30 min at RT.
A preembedding silver-intensified immunogold method and an immunoperoxidase method were used for the colocalization of CB 1 R and D 2 R in mouse PFC sections. Two primary polyclonal antibodies were used in this study: goat CB 1 R raised against a 31 aa C-terminal sequence (GenBank accession number NM007726) of the mouse CB 1 R (CB1-GoAf450-1; Frontier Science) and rabbit D 2 R raised against a 28 aa sequence (amino acids 284-311) within the third cytoplasmic loop of the human D 2 R, which is common to both long and short forms of the receptor (AB5084P; Millipore Bioscience Research Reagents). The CB 1 R (2 g/ ml) and D 2 R (5 g/ml) antibodies prepared in 10% BSA/TBS containing 0.1% sodium azide and 0.004% saponin were incubated simultaneously in PFC tissue on a shaker for 2 d at 4°C.
After several washes in 1% BSA/TBS, sections were incubated in a secondary 1.4 nm gold-labeled rabbit anti-goat IgG (FabЈ fragment, 1:100; Nanoprobes) for the detection of CB 1 R and in a biotinylated donkey anti-rabbit IgG (1:200; Jackson ImmunoResearch) for the detection of D 2 R, in both 1% BSA/TBS with 0.004% saponin on a shaker for 4 h at RT. PFC tissue was washed in 1% BSA/TBS and processed by a conventional avidin-biotin horseradish peroxidase complex method (ABC Elite; Vector Laboratories). The sections were washed in 1% BSA/TBS overnight at 4°C and postfixed in 1% glutaraldehyde in TBS for 10 min at RT. After washes in double-distilled water, gold particles were silver intensified with an HQ Silver kit (Nanoprobes) for ϳ12 min in the dark and then washed in 0.1 M PB, pH 7.4. The tissue was preincubated subsequently with 0.05% DAB in 0.1 M PB for 5 min, incubated by adding 0.01% hydrogen peroxide to the same solution for 5 min, and washed in 0.1 M PB for 2 h at RT. Stained sections were osmicated (1% OsO 4 in 0.1 M PB, pH 7.4, 20 min), dehydrated in graded alcohols to propylene oxide, and plastic-embedded flat in Epon 812. Ultrathin sections (80 nm) were collected on mesh nickel grids, stained with lead citrate, and examined in a Philips EM2008S electron microscope. Tissue preparations were photographed by using a digital camera coupled to the electron microscope.
Specificity of the immunostainings was assessed as follows: CB 1 R antibodies were incubated in CB 1 R Ϫ/Ϫ PFC tissue in the same conditions as above. In this case, CB 1 R immunolabeling was not observed in cortical synapses of CB 1 R deficient mice (data not shown). The D 2 R antibodies gave a similar faint cortical pattern as described in the light microscopy in previous publications using the same antiserum (Wang and Pickel, 2002; Lei et al., 2004) . In addition, no specific staining was detected in sections in which the primary D 2 R antibodies were replaced by goat serum (data not shown). Figure compositions were scanned at 300 dots per inch. Labeling and minor adjustments in contrast and brightness were made using Adobe Photoshop (CS; Adobe Systems).
Quantitative analysis of electron microscopy images. The quantitative analysis was made in layer 5/6 of PFC sections obtained from three mice processed for CB 1 R/D 2 R colocalization with preembedding immunocytochemistry. PFC sections, 50 m thick, from each animal showing good and reproducible DAB immunoreaction (D 2 R) and silver-intensified gold particles (CB 1 R) were cut at 80 nm. Electron micrographs (18,000 -28,000ϫ) were taken from grids (132 m side) containing DAB immunodeposits; all ultrathin sections showed a similar DAB labeling intensity, indicating that selected areas were at the same depth. Positive CB 1 R labeling was determined by observation of at least one immunoparticle within ϳ30 nm of the plasmalemma of axon terminals forming symmetrical-type synapses. Presynaptic boutons with D 2 R immunodeposits making symmetrical synapses were also counted. Percentages of presynaptic inhibitory-like profiles positive for CB 1 R or D 2 R were analyzed and displayed using a statistical software package (GraphPad Prism 4; GraphPad Software). Finally, the percentage of CB 1 Rpositive terminals at symmetrical synapses that colocalize with D 2 R as well as the percentage of immunoreactive D 2 R axonal boutons with CB 1 R immunolabeling that form symmetrical synapses were also analyzed. Data are presented as mean Ϯ SEM. A total of 250 inhibitorylike presynaptic axon terminals in an area of 642.492 m 2 were measured and analyzed by NIH ImageJ (version 1.36).
Electrophysiological recordings. All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Acute prefrontal cortical slices were prepared from postnatal day 16 (P16) to P25 Wistar rats and P24 -P46 C57BL/6 mice from Charles River Laboratories or from our colony of Zimmer line CB 1 R Ϫ/Ϫ mice (Zimmer et al., 1999) . The CB 1 R Ϫ/Ϫ mouse colony was maintained as heterozygotes and genotyped before use as described previously . Male and female animals were anesthetized with isoflurane and decapitated, and their brains were removed to a chilled cutting solution consisting of the following (in mM): 215 sucrose, 2.5 KCl, 26 NaHCO 3 , 1.6 NaH 2 PO 4 , 1 CaCl 2 , 4 MgCl 2 , 4 MgSO 4 , and 20 glucose. The posterior end of the brain was truncated flat with a razor blade, and then the brain was positioned in the cutting chamber with the cut end on the bottom. Coronal slices (350 m thick) were cut with a DTK-2000 (Dosaka) or Leica VT1200 S (Leica Microsystems) vibrating microslicer. Rostral sections containing the prelimbic-infralimbic region of the PFC were stored at room temperature in holding solution containing the following (in mM): 63 NaCl, 2.5 KCl, 22 NaHCO 3 , 1.4 NaH 2 PO 4 , 1.1 CaCl 2 , 3.2 MgCl 2 , 2 MgSO 4 , 15.5 glucose, and 107.5 sucrose. Thirty minutes after sectioning, slices were placed in extracellular recording solution containing the following (in mM): 126 NaCl, 2.5 KCl, 18 NaHCO 3 , 1.2 NaH 2 PO 4 , 1.2 CaCl 2 , 2.4 MgCl 2 , and 11 glucose. All solutions were saturated with 95% O 2 and 5% CO 2 , pH 7.4. Slices were incubated for at least 30 min in the recording solution before experiments.
All experiments were conducted in a submersion-type recording chamber perfused at ϳ2 ml/min, and the recording temperature was maintained at 30 Ϯ 1°C using a TC-344B dual-channel heater controller (Warner Instruments). Whole-cell patch-clamp experiments were performed in 10 M 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX) or CNQX (AMPAR/kainate receptor antagonists) and 25 M APV (NMDAR antagonist). In recordings of miniature IPSCs (mIPSCs), 1 M tetrodotoxin was additionally applied in the bath. To record GABA A R-mediated IPSCs, layer 5 pyramidal cells were voltage clamped at 0 mV using patch-type pipettes filled with intracellular solution containing the following (in mM): 131 Cs-gluconate, 8 NaCl, 1 CaCl 2 , 10 EGTA, 10 glucose, 10 HEPES, 5 MgATP, and 0.4 Na 3 GTP, pH 7.2 (285 mmol/kg). In experiments with postsynaptic calcium chelators, 20 mM Cs and 10 mM EGTA was replaced with 20 mM BAPTA. In some experiments, we assessed the electrophysiological properties of the patched pyramidal cells using a K-based internal solution containing the following (in mM): 130 K-gluconate, 10 NaCl, 0.2 EGTA, 10 HEPES, 5 MgATP, and 0.4 Na 3 GTP, pH 7.2 (285 mmol/kg). Series resistance (typically 5-15 M⍀) was monitored throughout the experiment with a Ϫ4 mV, 80 ms voltage step, and recordings with a Ͼ10% change in series resistance were excluded from analysis.
Stimulating electrodes were filled with extracellular recording solution and placed in layer 2/3 to stimulate distal inhibitory inputs and layer 5 to stimulate proximal inhibitory inputs. Patched cells were typically no more than 50 m lateral from the tips of stimulating electrodes. Each pathway was stimulated every 20 s, and synaptic responses typically ranged from 200 to 800 pA. I-LTD in the rat was triggered in layer 2/3 inputs by a 5 Hz train of synaptic stimulation lasting 10 min, at twice the test stimulus intensity. In the mouse PFC, a shorter 5 Hz train (5 min) was required to induce I-LTD. Stimulation was triggered by a Master-8 pulse generator (A.M.P.I.), and acquisition was controlled by customwritten software in Igor Pro 4.09A (Wavemetrics). Whole-cell patchclamp recordings were performed using a Multiclamp 700B amplifier (Molecular Devices).
To assess the efficacy of loading protein kinase A inhibitor (PKI) 6 -22 peptide in the patch pipette to inhibit postsynaptic PKA activity, experiments were performed in the CA1 region to monitor slow afterhyperpolarization potential currents (I AHP ), which is modulated by PKA activation (Pedarzani and Storm, 1993) . Transverse hippocampal slices (400 m) were prepared from P23-P25 Wistar rats. Slow I AHP were elicited by a depolarizing step (between 60 and 70 mV) for 100 ms in CA1 pyramidal cells voltage clamped between Ϫ50 to Ϫ55 mV with intracellular solution containing the following (in mM): 120 K-gluconate, 20 KCl, 15 HEPES, 2 Mg-ATP, 0.2 GTP, 1 MgCl 2 , and 0.1 EGTA. Sp-cAMPS at 50 M was used to inhibit the slow I AHP component, and the I AHP amplitude was measured 15-20 min after Sp-cAMPS application under control conditions or in cells loaded with 2.5 or 100 M PKI 6 -22.
Quantitative analysis of electrophysiological data. All values are provided as mean Ϯ SEM. The paired-pulse ratio (PPR) was defined as the ratio of the amplitude of the second IPSC over the amplitude of the first IPSC. The magnitude of drug effects was calculated as the percentage change between baseline (averaged responses for the 10 min before drug application) and 20 -30 min after start of WIN 55,212
application, 10 -15 min after start of quinpirole application or 20 -30 min after the start of bromocriptine application. The magnitude of I-LTD was calculated as the percentage change between baseline and 20 -30 min after complete delivery of tetanus. Statistical analysis was performed using Student's independent t test at the p Ͻ 0.05 significance level in OriginPro 7.0 software (OriginLab Corp), unless otherwise stated.
Drugs. WIN 55,212-2, (Ϫ)-quinpirole hydrochloride, bromocriptine (3,5-dinitrocatechol) , and picrotoxin were purchased from Tocris Bioscience. PKI 6 -22 and PKI 14 -22 peptides were obtained from either Tocris Bioscience or BIOMOL Research Laboratories. SpcAMPS was acquired from BIOMOL Research Laboratories. D-APV, NBQX, CNQX, 2-methyl-6-(phenylethynyl)-pyridine (MPEP) hydrochloride, and AM 251
were obtained from Ascent Scientific. H89 was procured from LC Labs. Total DMSO in the bath solution was maintained at 0.1% or below in all experiments.
Results
Anatomical evidence for CB 1 R and D 2 R presynaptic colocalization in the mouse PFC We first assessed anatomically whether CB 1 Rs and D 2 Rs colocalize at inhibitory synaptic terminals in the PFC. Double immunoelectron microscopy was used to precisely determine the localization of CB 1 Rs and D 2 Rs in layers 2/3 ( Fig. 1 A, B ) and 5/6 (Fig. 1C-F ) of the mouse PFC. Immunoperoxidase labeling of D 2 Rs (thick arrows) and immunogold labeling of CB 1 Rs (thin arrows) was frequently observed within axonal profiles in both layers ( Fig.  1 A-F ), which formed symmetrical synapses onto small postsynaptic dendrites and somatic membranes. CB 1 R immunoparticles were consistently associated with portions of presynaptic membranes away from the active zones, as expected for its known perisynaptic localization. To assess the degree of colocalization between CB 1 Rs and D 2 Rs, quantitative measurements were performed in layer 5/6 of PFC sections (Fig. 1G) . Notably, ϳ50% of relatively small presynaptic boutons with restricted immunoreaction for the D 2 R colocalized with CB 1 R immunoparticles along their membranes. A similarly high proportion of inhibitory presynaptic boutons with CB 1 R immunolabeling also contained D 2 R immunoreactivity. Although this number is probably an underestimation, ϳ30% of presynaptic boutons with pleomorphic synaptic vesicles and symmetrical synapses were immunonegative for both CB 1 R and D 2 R in layers 5/6. The high number of symmetrical synapses expressing either CB 1 R or D 2 R suggests that eCBs and DA play significant roles in modulating inhibitory transmission in the PFC. The superficial layer 2/3 also exhibited the same pattern of CB 1 R/D 2 R colocalization in presynaptic terminals impinging symmetrically on postsynaptic membranes of cell bodies and small-diameter dendrites ( Fig.  1 A, B) . Thus, our electron microscopy (EM) images reveal a strong pattern of colocalization between CB 1 Rs and D 2 Rs at terminals of symmetrical, presumably inhibitory, synapses in both layers 2/3 and 5/6 of the mouse PFC.
Pharmacological activation of CB 1 Rs or D 2 Rs suppresses
GABAergic transmission in mouse and rat PFC, most likely via a presynaptic mechanism Because both CB 1 Rs and D 2 Rs are present at terminals of symmetrical presumably GABAergic synapses, we next tested whether activation of these receptors has any functional effect on GABAergic synaptic transmission. Whole-cell recordings of pharmacologically isolated IPSCs were obtained from layer 5 pyramidal cells in acute mouse PFC slices. The identity of pyramidal cells was confirmed by assessment of electrophysiological properties and pyramidal cell-like morphology under infrared-differential interference contrast (IR-DIC) microscopy ( Fig. 2 A) . Exogenous bath application of the CB 1 R agonist WIN 55,212-2 (5 M) suppressed IPSCs evoked by focal stimulation via electrodes placed distally in layer 2/3 as well as proximally in layer 5 (Fig. 2 B) . IPSC amplitudes after WIN application were 49.4 Ϯ 7.9 and 56.3 Ϯ 9.9% of baseline in layer 2/3 and layer 5, respectively (n ϭ 4). Consistent with a reduction in GABA release, PPR increased from 0.83 Ϯ 0.03 to 0.94 Ϯ 0.04 in layer 2/3 ( p Ͻ 0.05) and from 0.84 Ϯ 0.03 to 0.92 Ϯ 0.04 in layer 5 ( p Ͻ 0.05). Similarly, activation of D 2 Rs by the agonist quinpirole (1 M) also depressed IPSCs evoked in both layers (Fig. 2C) . IPSC amplitudes after quinpirole application were 61.3 Ϯ 8.6 and 59.3 Ϯ 8.9% of baseline in layer 2/3 and layer 5, respectively (n ϭ 6). This reduction was associated with a change in PPR in both layers (layer 2/3, from 0.84 Ϯ 0.06 to 0.94 Ϯ 0.05; layer 5, from 0.76 Ϯ 0.03 to 0.93 Ϯ 0.06, p Ͻ 0.05). Thus, activation of CB 1 Rs or D 2 Rs decreases GABAergic transmission in the mouse PFC, most likely via a reduction in GABA release.
WIN and quinpirole inhibition of GABAergic transmission is not exclusive to the mouse PFC. In rat PFC slices, IPSCs evoked by stimulating in layer 2/3 and recording from layer 5 pyramidal cells were also suppressed by 5 M WIN to 41.4 Ϯ 4.5% of baseline (n ϭ 5) after WIN application, and PPR increased from 0.77 Ϯ 0.09 to 0.89 Ϯ 0.09 ( p Ͻ 0.01, paired t test) (Fig. 3A) . The suppression was indeed mediated by CB 1 Rs because preincubation with the antagonist AM 251 (4 M) abolished the WIN effect (91.8 Ϯ 3.9% of baseline, n ϭ 5, p Ͻ 0.005). GABAergic inputs in the rat were also sensitive to quinpirole because bath application of this D 2 R agonist reduced IPSCs to 66.9 Ϯ 4.6% of baseline (n ϭ 8), an effect that is accompanied by a change in PPR from 0.71 Ϯ 0.07 to 0.81 Ϯ 0.05 ( p Ͻ 0.05) (Fig. 3B) . Preincubation with the D 2 R antagonist sulpiride (10 M) blocked quinpirole-induced suppression of GABAergic transmission (99.0 Ϯ 3.8% of baseline, n ϭ 6, p Ͻ 0.005), supporting a role for D 2 Rs in this quinpirole effect. Moreover, a different and selective D 2 R agonist, bromocriptine (2 M), also suppressed IPSCs, reducing the amplitude to 72.5 Ϯ 4.2% of baseline (n ϭ 6, p Ͻ 0.005) along with a change in PPR from 0.85 Ϯ 0.04 to 0.99 Ϯ 0.07 ( p Ͻ 0.05, paired t test). Sulpiride also blocked the suppression by bromocriptine (102.5 Ϯ 3.6% of baseline, n ϭ 6, p Ͻ 0.005). In the striatum, D 2 R activation may lead to eCB mobilization (Giuffrida et al., 1999; Yin and Lovinger, 2006) , leading to a reduction in neurotransmitter release via CB 1 R activation (Yin and Lovinger, 2006) . To explore this possibility in the PFC, we examined the role of CB 1 Rs in quinpirole suppression of IPSCs; however, AM 251 did not block suppression by quinpirole (60.2 Ϯ 9.5% of baseline, n ϭ 5, p Ͻ 0.05). Together with the EM data showing presynaptic localization of CB 1 Rs and D 2 Rs, the PPR changes after WIN or quinpirole application support a functional role for CB 1 Rs and D 2 Rs in modulating GABA release in both mouse and rat PFC.
Endogenous PKA activity is critical for basal release of GABA and is most likely involved in the suppression of inhibitory transmission by WIN and quinpirole in the PFC Both CB 1 Rs and D 2 Rs are coupled to G i/oproteins, and their activation leads to inhibition of the AC/cAMP/PKA pathway (Howlett et al., 2004; Neve et al., 2004) , which may be responsible for the suppression of IPSCs in the PFC by WIN (Figs.  2 B, 3A) and by quinpirole (Figs. 2C, 3B ). If this were the case, we expect that directly blocking PKA activity with the inhibitor H89 should also reduce basal GABA release in the PFC. As in the hippocampus (Chevaleyre et al., 2007) , bath application of 10 M H89 resulted in a reduction of IPSCs to layer 5 pyramidal cells (65.0 Ϯ 7.4% of baseline, n ϭ 6), which was accompanied by a change in PPR (from 0.72 Ϯ 0.03 to 0.84 Ϯ 0.03, p Ͻ 0.05, paired t test) (Fig. 4A) . It is known that inhibition of voltage-gated calcium channels (VGCCs) and PKA contribute to CB 1 R-mediated depression of inhibitory transmission (Chevaleyre et al., 2006; Lovinger, 2008; Heifets and Castillo, 2009; Kano et al., 2009 ); thus, we examined the contribution of PKA in WIN suppression in the PFC by measuring spontaneous miniature IPSCs (mIPSCs) to reduce contamination by the VGCC-sensitive component (Fig. 4 B) . As reported previously (Vaughan et al., 1999; Takahashi and Linden, 2000; Trettel and Levine, 2002; Chevaleyre et al., 2007) , WIN (5 M) reduced mIPSC frequency (from 4.14 Ϯ 0.99 to 2.00 Ϯ 0.41 Hz, n ϭ 4, p Ͻ 0.05, paired t test) but not amplitude (from 11.3 Ϯ 1.8 to 10.5 Ϯ 1.5 pA, p Ͼ 0.05, paired t test). Preincubating PFC slices in 10 M H89 lowered mIPSC frequency (1.62 Ϯ 0.29 Hz, n ϭ 5, p Ͻ 0.05) and occluded additional reduction by subsequent WIN application (1.50 Ϯ 0.19 Hz, n ϭ 5, p Ͼ 0.05, paired t test). The mechanism by which D 2 Rs suppress GABA release is less clear. One study in the ventral tegmental area (VTA) suggests that activation of D 2 Rs at the presynaptic terminal may suppress inhibitory transmission solely via a decrease in PKA activity (Pan et al., 2008) . Another study using two-photon calcium imaging of axonal varicosities of VTA medium spiny neurons also implicate calcium sources in D 2 R-mediated inhibition (Mizuno et al., 2007) . We tested whether quinpirole suppression is sensitive to PKA inhibition and found that, in slices preincubated in H89, evoked IPSC amplitudes were unchanged after quinpirole application (108.9 Ϯ 9.4% of baseline, n ϭ 4) (Fig. 4C) . To confirm that the lack of quinpirole suppression in H89 indeed resulted from inhibition of PKA activity, we also used the potent cellmembrane-permeable PKA inhibitor peptide PKI 14 -22 and found similar block of the quinpirole effect (97.4 Ϯ 6.1% of baseline, n ϭ 6, p Ͻ 0.005). Thus, our results strongly suggest that PKA activity is involved in basal GABA release, and, by inhibiting this activity, CB 1 Rs or D 2 Rs can suppress GABAergic transmission.
Pharmacological activation of D 2 Rs facilitates induction of I-LTD
Our EM images show colocalization of CB 1 Rs and D 2 Rs at terminals of symmetrical synapses in the PFC, and we have provided functional evidence that independent activation of either receptor suppresses GABA release. Given that both CB 1 Rs and D 2 Rs can signal via PKA inhibition (Howlett et al., 2004; Neve et al., 2004) , we next wondered whether simultaneous activation of both receptors will reveal an interaction between D 2 R-and CB 1 R-mediated effects. To this aim, we applied a low dose of quinpirole (500 nM) in the absence or presence of a submaximal concentration of WIN (50 nM) (Fig. 5A) . Interestingly, although by itself 500 nM quinpirole had very little effect of basal IPSC amplitude (96.2 Ϯ 6.2% of baseline, n ϭ 10), it significantly decreased IPSCs when CB 1 Rs were coactivated (78.4 Ϯ 10.7% of baseline, n ϭ 8, p Ͻ 0.05). We next tested whether D 2 R activation could enhance eCB signaling in the PFC by delivering a 5 Hz train of synaptic stimulation (see Materials and Methods) in the presence of 500 nM quinpirole. Although on its own the 5 Hz stimulation was below threshold to trigger I-LTD, it became suprathreshold when D 2 Rs were activated (Fig. 5B) . IPSC amplitudes after train were 97.6 Ϯ 11.0% of baseline (n ϭ 5) and 60.6 Ϯ 3.3% of baseline (n ϭ 14) in the absence and presence of quinpirole, respectively ( p Ͻ 0.005). Consistent with a role for D 2 Rs, I-LTD was abolished in the presence of sulpiride (98.6 Ϯ 2.2% of baseline, n ϭ 4, p Ͻ 0.01) (Fig. 5C) . Importantly, I-LTD was dependent on CB 1 R activation because it was blocked in AM 251 (99.6 Ϯ 11.9% of baseline, n ϭ 5, p Ͻ 0.01) (Fig. 5D ) and was occluded by preincubation with 5 M WIN (99.1 Ϯ 7.6% of baseline, n ϭ 6, p Ͻ 0.01) (Fig. 5E) .
In many brain regions, eCB mobilization in LTD is triggered by activation of group I metabotropic glutamate receptors (mGluRs) (Chevaleyre et al., 2006; Heifets and Castillo, 2009; Kano et al., 2009) . Given evidence of the expression of these receptors in cell bodies and dendritic bundles of PFC pyramidal cells in layer 5 (Defagot et al., 2002; Lafourcade et al., 2007) , we next examined the involvement of group I mGluRs in I-LTD. Indeed, I-LTD was abolished by the group I mGluR antagonists LY367385 and MPEP (98.9 Ϯ 8.9% of baseline, n ϭ 6, p Ͻ 0.005), whereas interleaved I-LTD controls were normal (55.7 Ϯ 5.2% of baseline, n ϭ 6) (Fig. 5F ). Thus, despite the need for quinpirole, I-LTD in the PFC is similar to the more classical form of eCB-LTD in other brain regions in that its induction requires group I mGluR activation.
DA facilitation of I-LTD most likely occurs via synergism between presynaptic D 2 R and CB 1 R signaling D 2 Rs may act at several sites to facilitate I-LTD. We investigated the different possibilities in the following experiments. First, we tested whether D 2 Rs postsynaptically enhance eCB production and release in the PFC as has been suggested in the striatum and VTA (Giuffrida et al., 1999; Melis et al., 2004; Yin and Lovinger, 2006) . Given that the AC/cAMP/PKA pathway is a principal effector of D 2 R-mediated effects (Neve et al., 2004) , we blocked PKA in the entire slice by bath application of H89 (10 M) or PKI 14 -22 (2.5 M) and compared this effect with inhibiting PKA specifically in the postsynaptic cell (Fig. 6A) . Consistent with a presynaptic site of action by D 2 Rs, bath application of H89 or PKI 14 -22 abolished I-LTD (92.6 Ϯ 4.9% of baseline, n ϭ 6, p Ͻ 0.01; and 97.0 Ϯ 14.3% of baseline, n ϭ 6, p Ͻ 0.01, respectively), whereas loading the membrane-impermeable PKI 6 -22 peptide (2.5 or 100 M) into the patch pipette did not prevent I-LTD (57.9 Ϯ 5.6% of baseline, n ϭ 4; and 53.8 Ϯ 5.1% of baseline, n ϭ 5, respectively). We verified that this loading procedure could reliably inhibit postsynaptic PKA by assaying the ability of the PKI peptide to reduce the PKA-dependent inhibition of the slow AHP current (I AHP ) in CA1 pyramidal cells. Interestingly, loading PKI 6 -22 at 2.5 or 100 M were equally effective at decreasing the inhibition of slow I AHP induced by bath application of the PKA activator Sp-cAMPS (Fig. 6 B) . Hence, although I-LTD in the PFC is dependent on PKA activity, it appears that postsynaptic PKA does not play a significant role.
Although inhibition of PKA activity is a main target of D 2 R signaling, alternative molecular players such as intracellular calcium stores have been linked to D 2 R-mediated effects (Nishi et al., 1997; Hernandez-Lopez et al., 2000) . We tested whether intracellular calcium rise is necessary for eCB mobilization in I-LTD by loading the postsynaptic cell with the fast calcium chelator BAPTA (Fig. 6C) . In the presence of quinpirole, the 5 Hz train of synaptic stimulation still led to a longlasting depression of IPSCs in the PFC (59.6 Ϯ 6.6% of baseline, n ϭ 5). Thus, similar to the hippocampus (Chevaleyre and Castillo, 2003) and amygdala (Azad et al., 2004) , I-LTD in the PFC does not require postsynaptic calcium increases, further bolstering the idea that postsynaptic D 2 Rs are not involved. Our findings that D 2 Rs also localize to presynaptic inhibitory-like terminals and that activation of these receptors may reduce GABA release via PKA inhibition make presynaptic D 2 Rs the most likely mediators of I-LTD facilitation.
In the hippocampus, the level of spontaneous GABAergic activity can determine whether I-LTD occurs (Heifets et al., 2008) . It was shown that I-LTD requires calcium increases at GABAergic terminals during the induction step, via the recruitment of calcium-dependent protein kinases and phosphatases. In the PFC, activation of D 2 Rs may increase interneuronal excitability and thus spontaneous inhibitory activity (Retaux et al., 1991; Grobin and Deutch, 1998) . Although this effect is not seen by all (Gorelova and Yang, 2000; Seamans et al., 2001; Tseng and O'Donnell, 2007) , it is formally possible that quinpirole may indirectly facilitate I-LTD in the PFC by enhancing the activity of interneurons whose terminals express CB 1 Rs. We examined whether sIPSC frequency increased in our hands after 500 nM quinpirole application but found no difference (20.8 Ϯ 4.0 Hz before vs 17.7 Ϯ 2.8 Hz after, p Ͼ 0.05, n ϭ 9). Thus, an increase in spontaneous inhibitory activity cannot account for the facilitatory effect of quinpirole on eCB signaling.
Endogenous DA facilitates I-LTD when catechol-O-methyltransferase is inhibited
Thus far, we have activated D 2 Rs by applying the specific receptor agonist quinpirole. We next sought to determine whether endogenous DA can also facilitate eCB signaling. It is possible that DA deafferentation that is inherent to the slicing procedure prevented the 5 Hz train from triggering I-LTD in the absence of quinpirole. To compensate for a reduction of DA levels that is highly expected in PFC slices, we pharmacologically blocked DA Effects of both drugs were blocked by sulpiride. However, AM 251 had no effect on quinpirole suppression. The number of experiments for each condition is indicated in parentheses. *p Ͻ 0.05, **p Ͻ 0.01, ***p Ͻ 0.005. catabolism and tested whether synaptic stimulation will trigger I-LTD under this recording condition (Fig. 7) . The major mammalian enzymes involved in the degradation of DA are catechol-O-methyltransferase (COMT) and monoamine oxidases, with relative contribution tilted toward COMT in the PFC (Karoum et al., 1994; Matsumoto et al., 2003; Yavich et al., 2007) . Thus, to effectively increase DA levels in PFC slices, we pharmacologically blocked COMT activity with the inhibitor OR 486 (2 M). The 5 Hz train failed to trigger I-LTD in the presence of OR 486 alone (100.4 Ϯ 21.1% of baseline, n ϭ 4) (supplemental Fig. S1 , available at www.jneurosci.org as supplemental material). Because DA can activate both D 1 Rs and D 2 Rs, with potentially opposing effects (Cepeda et al., 1993; Nishi et al., 1997; Seamans et al., 2001; Trantham-Davidson et al., 2004; Tseng and O'Donnell, 2004; Xu et al., 2009) , an effect by D 2 Rs may potentially be masked by a conflicting D 1 R effect, depending on which receptor was more strongly activated. Therefore, we next tested I-LTD by coapplication of OR 486 with the D 1 R antagonist SCH23390 (10 M). Indeed, in the presence of OR 486 and SCH23390, I-LTD could be triggered by the 5 Hz synaptic stimulation (IPSC amplitude, 49.6 Ϯ 4.6% of baseline, n ϭ 10) (Fig. 7A) . Consistent with a reduction in probability of GABA release, PPR in I-LTD experiments increased from 0.82 Ϯ 0.03 to 0.92 Ϯ 0.04 ( p Ͻ 0.05, paired t test). A role for D 2 Rs was confirmed by the ability of sulpiride to reduce I-LTD in the presence of OR 486 (88.5 Ϯ 8.4% of baseline, n ϭ 8, p Ͻ 0.005) (Fig. 7A) . As was observed for the quinpirole-facilitated form, I-LTD in OR 486 and SCH23390 was also sensitive to CB 1 R blockade with AM 251 (93.0 Ϯ 9.8% of baseline, n ϭ 6, p Ͻ 0.01) (Fig. 7B) and was not present in the CB 1 R knock-out mice (knock-out, 92.2 Ϯ 4.8% of baseline, n ϭ 7 vs WT, 70.7 Ϯ 3.8% of baseline, n ϭ 7, p Ͻ 0.005) (Fig. 7C) . Consistent with a role for PKA in D 2 R-and CB 1 R-mediated effects on GABAergic transmission in the PFC, I-LTD in the presence of OR 486 and SCH23390 was reduced in H89 (91.0 Ϯ 5.7% of baseline, n ϭ 6, p Ͻ 0.005) (Fig. 7D) . Thus, together, our results strongly suggest that endogenous DA can activate D 2 Rs in the presynaptic GABAergic terminal to enhance eCB signaling and trigger I-LTD.
Discussion
In this study, we combine anatomical and electrophysiological techniques to investigate the cellular mechanisms underlying the link between DA and eCB function in the PFC. Using EM, we first show immunolabeling of D 2 Rs and CB 1 Rs at terminals of symmetrical presumably GABAergic synapses in the PFC. Notably, quantitative analysis reveal a robust pattern of CB 1 R and D 2 R colocalization at these presynaptic sites. Consistent with this localization, activation of either receptor suppresses GABA release as indicated by an increase in PPR. Importantly, repetitive afferent stimulation in the presence of a D 2 R agonist induces eCB-dependent I-LTD that is insensitive to interference of Previous studies have shown that activation of CB 1 Rs in neocortex (Trettel and Levine, 2002; Bodor et al., 2005; Hill et al., 2007; Galarreta et al., 2008) or D 2 Rs in prefrontal cortex (Retaux et al., 1991; Seamans et al., 2001) can suppress inhibitory transmission, presumably by reducing GABA release. Our combined anatomical and physiological data support similar roles of CB 1 Rs and D 2 Rs on GABAergic transmission in the PFC. Furthermore, in keeping with a recent report in the nucleus accumbens (Pickel et al., 2006) , we have found that D 2 Rs and CB 1 Rs can colocalize to sites presynaptic to symmetrical synapses in the PFC; this colocalization may provide an anatomical substrate for receptor interaction when coactivated. Coactivation of CB 1 Rs and D 2 Rs can have several potential effects on signal transduction of the respective individual receptors. In heterologous systems and striatal cultures, pharmacological coactivation of coexpressed CB 1 Rs and D 2 Rs has been shown to alter G-protein signaling, converting G i/o -mediated pathways to G scoupled ones (Glass and Felder, 1997; Kearn et al., 2005) , thereby enhancing rather than reducing transmitter release. There is also the possibility of synergistic or antagonistic crosstalk between the receptor systems in the presynapse (Kearn et al., 2005; Marcellino et al., 2008) .
We have tested for a potential interaction between the eCB and DA systems in the PFC and found that nominal activation of D 2 Rs with a low dose of quinpirole can facilitate eCB signaling at GABAergic synapses to trigger I-LTD. D 2 Rs most likely act by enhancing a process downstream of eCB mobilization from the postsynaptic cell because blocking postsynaptic PKA activity has no effect on I-LTD, whereas global block of PKA in the slice does. D 2 Rs may signal via pathways other than PKA. In the striatum, activation of D 2 Rs has been shown to lead to stimulation of phospholipase C␤ isoforms and mobilization of intracellular calcium stores (Nishi et al., 1997; Hernandez-Lopez et al., 2000) . However, two lines of evidence argue against a role for postsynaptic D 2 Rs in facilitating I-LTD in the PFC. First, quinpirole suppression of IPSCs is completely insensitive to AM 251, indicating that D 2 R activation is insufficient to trigger eCB production in the PFC. Second, intracellular calcium rise is not required for I-LTD because loading the postsynaptic cell with BAPTA has no effect on plasticity. Because both CB 1 R and D 2 R signaling can lead to inhibition of the PKA pathway, we postulate that coactivation of CB 1 Rs and D 2 Rs enables I-LTD in the PFC by cooperatively lowering PKA activity below a threshold level as supported by our observation of an enhancement of quinpirolemediated suppression by a submaximal concentration of WIN (Fig. 5A) . A similar mechanism has been suggested recently for I-LTD in the VTA (Pan et al., 2008 ). The precise molecular PKA target underlying I-LTD remains to be identified.
It is widely accepted that DA modulates PFC function. Here, we show that DA may influence synaptic transmission and plasticity in the PFC by facilitating eCB signaling via presynaptic D 2 Rs. Interestingly, our results using the COMT inhibitor OR 486 alone, in the absence of the D 1 R antagonist SCH23390 (supplemental Fig. S1 , available at www.jneurosci.org as supplemental material), suggest that D 1 R activation may antagonize D 2 Rfacilitated I-LTD. This raises the question of whether DA likely facilitates I-LTD in the intact brain. However, some evidence suggests that D 1 Rs and D 2 Rs may be selectively activated in vivo. D 2 Rs show comparatively higher affinity to DA than D 1 Rs (Creese et al., 1983) , and thus D 2 R activation may require lower concentrations of DA. It has been proposed, at least in the nucleus accumbens, that basal DA release continuously activate D 2 Rs, whereas phasic DA release is needed to elevate DA levels enough to stimulate D 1 Rs (Grace, 1991) . Moreover, tonic versus phasic DA transmission can be differentially evoked by distinct sets of afferents to DA neurons (Goto and Grace, 2005) . It is possible that D 2 Rs may be preferentially activated during tonic DA release conditions in the PFC as well, making GABAergic synapses primed for eCB signaling and I-LTD.
It is unclear how activation of D 1 Rs opposes PFC I-LTD in our experiments; D 1 Rs may directly antagonize downstream D 2 R/ CB 1 R signaling in the GABAergic terminal and/or mediate I-LTP at the same or different GABAergic synapse. We have shown with EM that a high proportion of presynaptic D 2 Rs are colocalized with CB 1 Rs (Fig. 1) , but the extent of overlap between presynaptic D 1 Rs and CB 1 Rs remains unknown. Furthermore, given the high expression of postsynaptic D 1 Rs in the PFC (Ariano and Sibley, 1994; Smiley et al., 1994; Lidow et al., 2003) , it is possible that these receptors mask I-LTD by mediating a potentiation of GABAergic transmission via an increase in number or conductance of GABA A receptors as has been shown for D 1 R and AMPAR (Sun et al., 2005) .
In the PFC, eCBs have been shown to depress excitatory transmission (Lafourcade et al., 2007) , and we now demonstrate that inhibitory transmission is also under eCB regulation. What, then, is the overall effect of eCBs on the balance of excitation and inhibition in the PFC and how is PFC output modulated? The answers to these questions may lie in the differential induction of E-LTD and I-LTD. It is interesting to note that eCB-mediated E-LTD in the PFC can be triggered by a slightly stronger synaptic stimulation train (e.g., 10 vs 5 Hz) and does not require DA transmission. Furthermore, postsynaptic calcium rise is necessary for E-LTD but not I-LTD, suggesting that multiple mechanisms underlying eCB production may exist. Future studies will be needed to examine whether DA can modulate this form of E-LTD. Interestingly, a form of E-LTD, induced by brief highfrequency (50 Hz) stimulation, has been described previously in the PFC to depend on DA (Otani et al., 1998) ; the involvement of eCB signaling in this E-LTD is yet to be determined. Another provocative question is whether synaptic activity can simultaneously trigger both eCB-mediated E-LTD and I-LTD. If so, it will be important to assess changes in the firing properties of the output layer 5 pyramidal cells in PFC under conditions of intact excitation and inhibition.
In humans, cannabis consumption has dramatic effects on PFC-mediated function and can trigger schizophrenia-like states in normal individuals, exacerbate psychotic symptoms in schizophrenic patients, and increase the risk of developing schizophrenia in predisposed individuals (Ujike and Morita, 2004; Koethe et al., 2009; Sewell et al., 2009) . In addition, studies using CB 1 Rdeficient mice have revealed an important role of eCBs in the extinction of learned behaviors, such as fear (Marsicano et al., 2002; Varvel and Lichtman, 2002) , which are partly mediated by the PFC (Morgan et al., 1993; Morrow et al., 1999) . It is currently unknown how eCBs and cannabinoid agonists can lead to these effects. The involvement of DA in the central actions of cannabinoids has been suggested (van der Stelt and Di Marzo, 2003; Laviolette and Grace, 2006) . Cannabinergic signaling may lead to DA release (Cadogan et al., 1997; van der Stelt and Di Marzo, 2003) and can modulate D 2 R agonist-induced behavior (Beltramo et al., 2000; Gorriti et al., 2005) . Indeed, microdialysis measurements have revealed an increase of DA in the PFC after in vivo administration of the cannabinoid ⌬(9)-tetrahydrocannabinol (Pistis et al., 2002) . Notably, a decrease of GABA in the PFC was also observed in this study. Given that an imbalance of excitatory and inhibitory transmission in the PFC has been proposed to contribute to schizophrenia (Lewis et al., 2005; Gonzalez-Burgos and Lewis, 2008) , these changes in neurotransmitter levels provide insight into how schizophrenic symptoms may emerge after cannabis consumption. We propose that a synergic interaction between DA and eCB function at the synaptic level in the PFC (i.e., to trigger I-LTD) may play a role in schizophrenia in predisposed cannabis users.
